TARGETING THE SIGMA-1/NMDA RECEPTOR COMPLEX TO AMELIORATE COGNITIVE DEFICITS AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

Łukasz Ćmok; Julia Dobrowolska; Justyna Chudy; Jakub Robert Skalski; Gabriela Daniel; Karolina Halat; Antoni Hajdas; Natalia Kaczmarczyk; Iga Kałka; Julia Szmuc

doi:10.31435/ijitss.1(49).2026.5596

Authors

Łukasz Ćmok Beskidzkie Centrum Onkologii, Municipal Hospital of John Paul II in Bielsko-Biała, Bielsko-Biała, Poland https://orcid.org/0009-0009-3414-4743
Julia Dobrowolska Wojewódzki Szpital Specjalistyczny nr 5 im. św. Barbary w Sosnowcu, Sosnowiec, Poland https://orcid.org/0009-0007-9647-2174
Justyna Chudy Beskidzkie Centrum Onkologii, Municipal Hospital of John Paul II in Bielsko-Biała, Bielsko-Biała, Poland https://orcid.org/0009-0006-8824-7260
Jakub Robert Skalski Szpital Miejski Specjalistyczny im. G. Narutowicza w Krakowie, Kraków, Poland https://orcid.org/0009-0006-5954-096X
Gabriela Daniel Szpital Powiatowy im. Miłosierdzia Bożego w Limanowej, Limanowa, Poland https://orcid.org/0009-0007-5590-8736
Karolina Halat Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Kraków, Poland https://orcid.org/0009-0001-2242-5814
Antoni Hajdas Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Kraków, Poland https://orcid.org/0009-0005-1836-6312
Natalia Kaczmarczyk The University Hospital (SU) in Krakow, Kraków, Poland https://orcid.org/0009-0000-4386-4333
Iga Kałka Szpital Specjalistyczny im. Stefana Żeromskiego w Krakowie, Kraków, Poland https://orcid.org/0009-0008-1527-4983
Julia Szmuc Szpital Specjalistyczny im. Stefana Żeromskiego w Krakowie, Kraków, Poland https://orcid.org/0009-0005-4403-3044

DOI:

https://doi.org/10.31435/ijitss.1(49).2026.5596

Keywords:

Schizophrenia, Sigma-1 Receptor, NMDA Receptor, Cognitive Deficits, Negative Symptoms

Abstract

Background: The main limitation of contemporary schizophrenia treatment is the insufficient clinical response of negative symptoms and cognitive deficits to current antipsychotics. In light of the NMDA receptor hypofunction hypothesis, research increasingly targets novel glutamatergic modulators.

Aim: This study analyzes the molecular mechanisms linking Sigma-1 receptor (σ1R) dysfunction with glutamate N-methyl-D-aspartate receptor (NMDAR) hypofunction in schizophrenia and assesses the therapeutic potential of σ1R agonists (e.g., fluvoxamine, pridopidine, AF710B) in reducing drug-resistant symptoms. It also examines their broader socioeconomic implications.

Methods: A narrative review of the literature was conducted using the PubMed database, primarily focused on publications from 2006 to 2026; however, earlier studies were incorporated if they provided crucial mechanistic insights. European Brain Council reports were also included.

Results: Accumulated evidence indicates that σ1R stabilizes NMDAR transport to the cell membrane and modulates its activity. Pharmacological stimulation by σ1R agonists promotes the restoration of synaptic plasticity and cellular homeostasis, effectively eliminating endoplasmic reticulum stress and inflammation. This results in the restoration of dendritic spine structure and a significant improvement in memory, cognitive flexibility, and social interactions.

Conclusion: Targeted modulation of the σ1R/NMDAR complex is a highly promising neuropharmacological strategy in schizophrenia management. Augmenting standard treatment with targeted σ1R agonists may effectively address the drug-resistant aspects of schizophrenia pathophysiology, paving the way for a significant improvement in patient functional prognosis.

References

Ahmed, M. K., Abdou, K., Ibrahim, W. W., Mohamed, A. F., & El-Boghdady, N. A. (2025). Sigma-1 receptor activation by fluvoxamine ameliorates ER stress, synaptic dysfunction and behavioral deficits in a ketamine model of schizophrenia. Journal of Neuroimmune Pharmacology, 20(1), 76. https://doi.org/10.1007/s11481-025-10231-4

Albayrak, Y., & Hashimoto, K. (2017). Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. Advances in Experimental Medicine and Biology, 964, 153–161. https://doi.org/10.1007/978-3-319-50174-1_11

Balu, D. T. (2016). The NMDA receptor and schizophrenia: From pathophysiology to treatment. Advances in Pharmacology, 76, 351–382. https://doi.org/10.1016/bs.apha.2016.01.006

Bui, V., Santerre, M., Shcherbik, N., & Sawaya, B. E. (2026). Mitochondria-associated membranes (MAMs): Molecular organization, cellular functions, and their role in health and disease. FEBS Open Bio, 16(1), 11–24. https://doi.org/10.1002/2211-5463.70121

Calzavara Pinton, I., Nibbio, G., Bertoni, L., Cicale, A., Necchini, N., Zardini, D., Bosco Ubertino, U., Cerati, C., Deste, G., Barlati, S., & Vita, A. (2024). The economic burden of schizophrenia spectrum disorders: Clinical and functional correlates and predictors of direct costs. A retrospective longitudinal study. Psychiatry Research, 342, 116240. https://doi.org/10.1016/j.psychres.2024.116240

Chen, J., Li, G., Qin, P., Chen, J., Ye, N., Waddington, J. L., & Zhen, X. (2022a). Allosteric modulation of the sigma-1 receptor elicits antipsychotic-like effects. Schizophrenia Bulletin, 48(2), 474–484. https://doi.org/10.1093/schbul/sbab137

Chen, Y., Li, S., Zhang, T., Yang, F., & Lu, B. (2022b). Corticosterone antagonist or TrkB agonist attenuates schizophrenia-like behavior in a mouse model combining Bdnf-e6 deficiency and developmental stress. iScience, 25(7), 104609. https://doi.org/10.1016/j.isci.2022.104609

Correll, C. U., Xiang, P., Sarikonda, K., Bhagvandas, N., & Gitlin, M. (2024). The economic impact of cognitive impairment and negative symptoms in schizophrenia: A targeted literature review with a focus on outcomes relevant to health care decision-makers in the United States. The Journal of Clinical Psychiatry, 85(3), 24r15316. https://doi.org/10.4088/JCP.24r15316

Coyle, J. T. (2006). Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cellular and Molecular Neurobiology, 26(4–6), 365–384. https://doi.org/10.1007/s10571-006-9062-8

Estévez-Silva, H. M., Cuesto, G., Romero, N., Brito-Armas, J. M., Acevedo-Arozena, A., Acebes, Á., & Marcellino, D. J. (2022). Pridopidine promotes synaptogenesis and reduces spatial memory deficits in the Alzheimer’s disease APP/PS1 mouse model. Neurotherapeutics, 19(5), 1566–1587. https://doi.org/10.1007/s13311-022-01280-1

European Brain Council. (2025). Rethinking schizophrenia in Poland. https://www.braincouncil.eu/rethinking-schizophrenia-in-poland-schizophrenia-and-brain-health/

Fisher, A., Bezprozvanny, I., Wu, L., Ryskamp, D. A., Bar-Ner, N., Natan, N., Brandeis, R., Elkon, H., Nahum, V., Gershonov, E., LaFerla, F. M., & Medeiros, R. (2016). AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer’s disease. Neurodegenerative Diseases, 16(1–2), 95–110. https://doi.org/10.1159/000440864

Fujimoto, M., Hayashi, T., Urfer, R., Mita, S., & Su, T. P. (2012). Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse, 66(7), 630–639. https://doi.org/10.1002/syn.21549

Grachev, I. D., Meyer, P. M., Becker, G. A., Bronzel, M., Marsteller, D., Pastino, G., Voges, O., Rabinovich, L., Knebel, H., Zientek, F., Rullmann, M., Sattler, B., Patt, M., Gerhards, T., Strauss, M., Kluge, A., Brust, P., Savola, J. M., Gordon, M. F., Geva, M., ... Sabri, O. (2021). Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: A [18F] fluspidine and [18F] fallypride PET study. European Journal of Nuclear Medicine and Molecular Imaging, 48(4), 1103–1115. https://doi.org/10.1007/s00259-020-05030-3

Jacobi, A. A., Halawani, S., Lynch, D. R., & Lin, H. (2019). Neuronal serine racemase associates with Disrupted-In-Schizophrenia-1 and DISC1 agglomerates: Implications for schizophrenia. Neuroscience Letters, 692, 107–114. https://doi.org/10.1016/j.neulet.2018.10.055

Jadi, M. P., Behrens, M. M., & Sejnowski, T. J. (2016). Abnormal gamma oscillations in N-methyl-D-aspartate receptor hypofunction models of schizophrenia. Biological Psychiatry, 79(9), 716–726. https://doi.org/10.1016/j.biopsych.2015.07.005

Ka, M., Kook, Y. H., Liao, K., Buch, S., & Kim, W. Y. (2016). Transactivation of TrkB by sigma-1 receptor mediates cocaine-induced changes in dendritic spine density and morphology in hippocampal and cortical neurons. Cell Death & Disease, 7(10), e2414. https://doi.org/10.1038/cddis.2016.319

Krasa, H. B., Baumgardner, J. R., Brewer, I. P., Chou, J. W., Flottemesch, T., Markowitz, J. T., Williams, C., & Nagendra, A. (2026). National and state societal costs of schizophrenia in the US in 2024. JAMA Psychiatry, Advance online publication. https://doi.org/10.1001/jamapsychiatry.2025.4383

Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., Heninger, G. R., Bowers, M. B., Jr., & Charney, D. S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51(3), 199–214. https://doi.org/10.1001/archpsyc.1994.03950030035004

Ma, T. M., Abazyan, S., Abazyan, B., Nomura, J., Yang, C., Seshadri, S., Sawa, A., Snyder, S. H., & Pletnikov, M. V. (2013). Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Molecular Psychiatry, 18(5), 557–567. https://doi.org/10.1038/mp.2012.97

Martínez, A. L., Brea, J., Rico, S., de Los Frailes, M. T., & Loza, M. I. (2021). Cognitive deficit in schizophrenia: From etiology to novel treatments. International Journal of Molecular Sciences, 22(18), 9905. https://doi.org/10.3390/ijms22189905

Moon, J. Y., Choi, S. R., Roh, D. H., Yoon, S. Y., Kwon, S. G., Choi, H. S., Kang, S. Y., Han, H. J., Kim, H. W., Beitz, A. J., Oh, S. B., & Lee, J. H. (2015). Spinal sigma-1 receptor activation increases the production of D-serine in astrocytes which contributes to the development of mechanical allodynia in a mouse model of neuropathic pain. Pharmacological Research, 100, 353–364. https://doi.org/10.1016/j.phrs.2015.08.019

Pabba, M., & Sibille, E. (2015). Sigma-1 and N-methyl-D-aspartate receptors: A partnership with beneficial outcomes. Molecular Neuropsychiatry, 1(1), 47–51. https://doi.org/10.1159/000376549

Pabba, M., Wong, A. Y., Ahlskog, N., Hristova, E., Biscaro, D., Nassrallah, W., Ngsee, J. K., Snyder, M., Beique, J. C., & Bergeron, R. (2014). NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. The Journal of Neuroscience, 34(34), 11325–11338. https://doi.org/10.1523/JNEUROSCI.0458-14.2014

Rafcikova, J., Novakova, M., & Stracina, T. (2023). Exploring the association between schizophrenia and cardiovascular diseases: Insights into the role of sigma 1 receptor. Physiological Research, 72(Suppl. 2), S113–S126. https://doi.org/10.33549/physiolres.935099

Ren, P., Wang, J., Li, N., Li, G., Ma, H., Zhao, Y., & Li, Y. (2022). Sigma-1 receptors in depression: Mechanism and therapeutic development. Frontiers in Pharmacology, 13, 925879. https://doi.org/10.3389/fphar.2022.925879

Ryskamp, D. A., Korban, S., Zhemkov, V., Kraskovskaya, N., & Bezprozvanny, I. (2019a). Neuronal sigma-1 receptors: Signaling functions and protective roles in neurodegenerative diseases. Frontiers in Neuroscience, 13, 862. https://doi.org/10.3389/fnins.2019.00862

Ryskamp, D., Wu, L., Wu, J., Kim, D., Rammes, G., Geva, M., Hayden, M., & Bezprozvanny, I. (2019b). Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor. Neurobiology of Disease, 124, 489–504. https://doi.org/10.1016/j.nbd.2018.12.022

Sahlholm, K., Århem, P., Fuxe, K., & Marcellino, D. (2013). The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the σ-1 receptor. Molecular Psychiatry, 18(1), 12–14. https://doi.org/10.1038/mp.2012.3

Sahlholm, K., Valle-León, M., Fernández-Dueñas, V., & Ciruela, F. (2018). Pridopidine reverses phencyclidine-induced memory impairment. Frontiers in Pharmacology, 9, 338. https://doi.org/10.3389/fphar.2018.00338

Steullet, P., Cabungcal, J. H., Coyle, J., Didriksen, M., Gill, K., Grace, A. A., Hensch, T. K., LaMantia, A. S., Lindemann, L., Maynard, T. M., Meyer, U., Morishita, H., O'Donnell, P., Puhl, M., Cuenod, M., & Do, K. Q. (2017). Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Molecular Psychiatry, 22(7), 936–943. https://doi.org/10.1038/mp.2017.47

Washburn, H. R., Xia, N. L., Zhou, W., Mao, Y. T., & Dalva, M. B. (2020). Positive surface charge of GluN1 N-terminus mediates the direct interaction with EphB2 and NMDAR mobility. Nature Communications, 11(1), 570. https://doi.org/10.1038/s41467-020-14345-6

Yang, Y., Zhang, Y., Hou, X., Li, H., Ma, H., & Li, Y. (2025). Hypidone hydrochloride (YL-0919), a sigma-1 receptor agonist, improves attention by increasing BDNF in mPFC. Pharmaceuticals, 18(4), 455. https://doi.org/10.3390/ph18040455

Yasui, Y., & Su, T. P. (2016). Potential molecular mechanisms on the role of the sigma-1 receptor in the action of cocaine and methamphetamine. Journal of Drug and Alcohol Research, 5, 235970. https://doi.org/10.4303/jdar/235970